April 23 (Bloomberg) -- GlaxoSmithKline Plc, Europe's biggest drugmaker, agreed to buy Sirtris Pharmaceuticals Inc. for about $720 million, adding an experimental treatment derived from red wine that's thought to slow the effects of aging.SRT501 mimics resveratrol, which has been linked to longevity, Sirtris scientists said. The ...